CT-996 – Talk Bio

Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate

2 months ago talkbio0Tagged ASC30, Ascletis, Clinical Trials, CT-996, Obesity, Oral cavity, Pharma, Pharmaceutical competition, Product containing glucagon-like peptide 1 receptor agonist (product), Roche (company)

Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition

Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results

7 months ago talkbio0Tagged aspects of adverse effects, concerns, Contraceptives, Oral, CT-996, Effectiveness, Gastrointestinal Issues, Nausea, Obesity, Roche (company), Safety, Vomiting

Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues

Eli Lilly, Novo Nordisk Shares Fall as their weight-Loss drugs face competition

9 months ago talkbio0Tagged CT-996, Eli, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, Obesity, Pharmaceutical competition, Roche, Stock market, Wegovy, weight-loss drug market

, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,